Jamie Samath sold $62k of ISRG
EVP & CFO & Enterprise Technol at INTUITIVE SURGICAL INC. 108 shares at an average of $570.85, traded Feb 26, 2025, filed Feb 27, 2025.
Score components
- +22RoleCFO
- +7Trade size$62k at market
- 0Share of holdings soldSold 2.2% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001035267-25-000046, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 26, 2025 | MOption exercise Common Stock10b5-1 | +1,281 | $0.00 | $0 | 4,563 | Feb 27, 2025 |
| Feb 26, 2025 | FTax withholding Common Stock10b5-1 | -635 | $573.74 | $364k | 3,928 | Feb 27, 2025 |
| Feb 26, 2025 | MOption exercise Common Stock10b5-1 | +1,908 | $0.00 | $0 | 5,836 | Feb 27, 2025 |
| Feb 26, 2025 | FTax withholding Common Stock10b5-1 | -946 | $573.74 | $543k | 4,890 | Feb 27, 2025 |
| Feb 26, 2025 | MOption exercise Common Stock10b5-1 | +54 | $347.42 | $19k | 4,944 | Feb 27, 2025 |
| Feb 26, 2025 | SOpen-market sale Common Stock10b5-1 | -54 | $570.85 | $31k | 4,890 | Feb 27, 2025 |
| Feb 26, 2025 | MOption exercise Common Stock10b5-1 | +54 | $245.60 | $13k | 4,944 | Feb 27, 2025 |
| Feb 26, 2025 | SOpen-market sale Common Stock10b5-1 | -54 | $570.85 | $31k | 4,890 | Feb 27, 2025 |
| Feb 26, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -54 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 26, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -54 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 26, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -1,281 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 26, 2025 | MOption exercise Restricted Stock Units - 2-26-2024derivative10b5-1 | -1,908 | $0.00 | $0 | 5,723 | Feb 27, 2025 |
| Feb 26, 2025 | AGrant or award Restricted Stock Units - 2-26-2025derivative10b5-1 | +5,951 | $0.00 | $0 | 5,951 | Feb 27, 2025 |
Related signals
Other insiders at INTUITIVE SURGICAL INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | INTUITIVE SURGICAL INC | Fredrik Widman VP Corporate Controller | $408k 1,089 shares | -69% | |
| 3Weak | INTUITIVE SURGICAL INC | Mark Brosius EVP & Chief Mfg and Supply Cha | $17k 48 shares | -6% | |
| 3Weak | INTUITIVE SURGICAL INC | Mark Brosius EVP & Chief Mfg and Supply Cha | $25k 69 shares | -8% | |
| 25Weak | INTUITIVE SURGICAL INC | Myriam Curet EVP & Chief Medical Officer | $2.2M 4,500 shares | -93% | |
| 18Weak | INTUITIVE SURGICAL INC | Mark Brosius SVP & Chief Mfg and Supply Cha | $242k 431 shares | -32% | |
| 20Weak | INTUITIVE SURGICAL INC | Mark Brosius SVP & Chief Mfg and Supply Cha | $355k 645 shares | -33% | |
| 10Weak | INTUITIVE SURGICAL INC | Mark Brosius SVP & Chief Mfg and Supply Cha | $24k 42 shares | -2% | |
| 16Weak | INTUITIVE SURGICAL INC | Mark Brosius SVP & Chief Mfg and Supply Cha | $37k 66 shares | -3% | |
| 18Weak | INTUITIVE SURGICAL INC | Jamie Samath See Remarks | $483k 915 shares | -11% | |
| 40Moderate | INTUITIVE SURGICAL INC | Amy L Ladd director | $4.4M 8,776 shares | -307% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.